---
title: "Zeo ScientifiX, Inc. (ZEOX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ZEOX.US.md"
symbol: "ZEOX.US"
name: "Zeo ScientifiX, Inc."
industry: "生物技術"
---

# Zeo ScientifiX, Inc. (ZEOX.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [www.zeoscientifix.com](https://www.zeoscientifix.com) |

## Company Profile

Zeo ScientifiX, Inc.是一家臨床階段的生物制藥公司，專注于開發用于治療退行性疾病和再生醫學的生物治療藥物。其主要產品候選藥物 Zofin 是一種源自圍產期的無細胞生物治療藥物，目前正在進行 I/II 期臨床試驗，旨在治療 COVID-19、慢性阻塞性肺病、骨關節炎和創傷性腦損傷。該公司還提供 Patient Pure X，這是一種自體生物制劑，有助于減少炎症並促進組織愈合和再生。此外，它還開發和分銷包含其專有成分的產品，用于局部美容應用；包括 ZEO GROWX、ZEO HAIR GROW 和 ZEO GROW BOOST，這是一種由促進毛囊刺激的生發刺激劑組成的精華液

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-25T04:30:15.000Z

**Overall: C (0.42)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 158 / 401 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 12.53% |  |
| Net Profit YoY | -17.34% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -12.98 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 18.47M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 5.20M |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 358.97% | A |
| Profit Margin | -106.19% | E |
| Gross Margin | 82.09% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 12.53% | B |
| Net Profit YoY | -17.34% | D |
| Total Assets YoY | -7.06% | D |
| Net Assets YoY | 13.91% | B |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -94.17% | D |
| OCF YoY | 12.53% | B |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 3.28 | A |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 193.19% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Zeo ScientifiX, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "358.97%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-106.19%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "82.09%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "12.53%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-17.34%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.06%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "13.91%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-94.17%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "12.53%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "3.28",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "193.19%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | 福泰制藥 (US.VRTX) | A | B | C | B | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.35 | 314/604 | - | - | - |
| PB | -12.98 | 536/604 | - | - | - |
| PS (TTM) | 3.55 | 79/604 | 3.59 | 2.85 | 2.47 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/ZEOX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ZEOX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ZEOX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.